Neural Blockade Monitor

Rethinking Anesthesia: Introducing the Neural Blockade Monitor

Anesthesiology has advanced dramatically over the past century—but at least one critical gap has remained: clinicians still lack a real-time, objective way to measure the effectiveness of regional anesthetics. Until now.

BIOPAC is proud to introduce the Neural Blockade Monitor (NBM)—a groundbreaking medical device technology that brings objective, non-invasive, real-time monitoring to the world of regional anesthesia. This innovation bridges decades of progress in anesthetic agents and techniques with the fundamental need for data-driven decision-making in clinical care.

Regional anesthetics, which block transmission of nerve signals from the source of pain to the brain, have revolutionized peri-operative pain management. But despite their widespread use, there has never been a reliable way to determine how well a nerve block is working—until the patient either feels pain, or doesn’t. The NBM changes that by enabling clinicians to see, in real time, how effectively a nerve block is working.

BIOPAC is developing this technology in collaboration with BLOCKsynop, Inc. and the Johns Hopkins University Applied Physics Laboratory (APL), the NBM offers:

• Real-time monitoring of nerve block location and density leading to Improved patient safety 

• Quantitative reporting of block effectiveness

• Targeted and informed dosing to reduce anesthetic toxicity

• Patient-specific precision in peri-operative regional anesthesia management

Through this partnership, BIOPAC has licensed the NBM technology and is working to bring it to market as a clinically validated medical device. We are transforming the way pain is managed—objectively, safely, and in real time.